Conference Presentations View by year: All 2025 2024 2023 2022 Filter 01 Oct 2022 CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors 01 Oct 2022 CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis® CD19 T cells results in significant tumor killing 01 Oct 2022 Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell 1 2 Investor Centre Welcome to Imugene Investor Centre ASX Announcements Investor Presentations Conference Presentations Financial Reports Analyst Coverage ESG Reports Media Videos Newsletters Investor Centre Welcome to Imugene Investor Centre ASX Announcements Investor Presentations Conference Presentations Financial Reports Analyst Coverage ESG Reports Media Videos Newsletters
01 Oct 2022 CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors
01 Oct 2022 CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis® CD19 T cells results in significant tumor killing
01 Oct 2022 Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell
